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Endothelial glycocalyx (GCX) has been reported as a protective factor for vascular endothelial cells 
(VEC) in diabetes and hypertension.   However,  the involvement of GCX impairment in ocular vascul-
opathy remains unclear.  We evaluated the changes in the GCX thicknesses of the retinal and choroidal 
capillaries in rats with diabetes and hypertension by cationic colloidal iron staining using a transmis-
sion electron microscope.  In the control group,  the mean (standard error of the mean) thicknesses of 
retinal and choroidal GCX were 60.2 (1.5) nm and 84.3 (3.1) nm,  respectively.  The diabetic rats showed 
a signiﬁcant decrease of GCX thickness in the retina,  but not in the choroid,  compared to controls 
(28.3 (0.3) nm,  p＜0.01 and 77.8 (1.4) nm,  respectively).  In the hypertensive rats,  both retinal and chor-
oidal GCX were signiﬁcantly decreased compared to the control values (10.9 (0.4) nm and 13.2 (1.0) nm,  
respectively,  both p＜0.01).  Moreover,  we could visualize the adhesion of leukocytes and platelets on 
the luminal surface of VEC,  at the site where the GCX was markedly degraded.  These ﬁndings sug-
gest that the GCX prevents adhesion of leukocytes and platelets to the VEC surface,  and this impair-
ment may lead to ocular vasculopathy in diabetes and hypertension.
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n diabetes and hypertension,  hyperglycemia and 
high blood pressure per se are potent pro-
inﬂammatory and pro-oxidant stimuli and play a key 
role in the pathogenesis of ocular vasculopathy [1].  
One major inﬂammatory reaction in the microvessels 
is leukocyte and platelet adhesion to vascular endothe-
lial cells (VEC) [2].  In the process of leukocyte-VEC 
adhesion,  it is well known that the bindings of adhe-
sion molecules such as integrin,  selectin,  intercellular 
adhesion molecule-1 (ICAM-1) and vascular cell adhe-
sion molecule-1 (VCAM-1) are important [3].  In 
regard to oxidative stress,  it has been reported that 
hyperglycemia,  advanced glycation end-product (AGE) 
and high blood pressure degrade VEC and thereby 
decrease their nitric oxide (NO) production,  leading 
to an increase of oxidative stress [4-6].  Recently,  it 
has been reported that the endothelial glycocalyx 
(GCX) plays an important role in the process of both 
leukocyte-VEC adhesion and decreased NO release 
through the degradation of VEC [7-9].
　 The GCX is a layer covering the intravascular 
lumen and consists of a negatively charged mesh of 
proteoglycans,  glycosaminoglycans,  glycoproteins and 
glycolipids derived from VECs [10].  The GCX has 
been shown to protect VEC and to orchestrate vascu-
lar homeostasis through the following actions: 1) 
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modulation of transendothelial permeability,  2) regu-
lation of leukocyte and platelet adhesion to VEC and 
3) mechanosensing of shear stress,  thereby mediating 
shear-induced release of NO by VEC [7,  11,  12].  In 
the heart,  brain and kidney,  it has been reported that 
diabetes and hypertension degrade endothelial GCX 
and lead to an increase in vascular permeability,  leu-
kocyte-VEC adhesion and oxidative stress [4,  8,  
13-16].  However,  it is uncertain whether diabetes 
and hypertension aﬀect the GCX of ocular microves-
sels,  especially the retinal and choroidal capillaries.
　 Here,  we hypothesized that the degradation of 
GCX plays an important role in the pathological pro-
cess of diabetic and hypertensive retino-choroidal 
vasculopathy.  To investigate this,  we visualized the 
retinal and choroidal capillary GCX in diabetic and 
hypertensive rats and determined their thickness 
quantitatively.  
Materials and Methods
　 Animals. All animal experiments adhered to 
the Association for Research in Vision and 
Ophthalmology (ARVO) Statement for the Use of 
Animals in Ophthalmic and Vision Research.  Male 
Wistar Kyoto rats (WKY) at 15 weeks of life and male 
spontaneous hypertensive rats (SHR) at 16 weeks of 
life (both from Charles River,  Tokyo,  Japan) were 
used for the experiments.  Animals were fed standard 
laboratory food and were allowed free access to water 
in an air-conditioned room with a 12-hour light/12-
hour dark cycle.  WKY (n＝5) were made diabetic by 
an intraperitoneal injection of streptozocin (60mg/
kg; Sigma,  St.  Louis,  MO,  USA) (STZ-WKY) 
[17].  Forty-eight hours after the injection,  the blood 
glucose level was monitored.  A blood glucose level of 
more than 250mg/dl was considered to represent 
hyperglycemia.  In the control group (n＝5),  citrate 
buﬀer solution was injected as a vehicle.  In both 
groups,  the visualization of glycocalyx,  as stated 
below,  was carried out on the 7th day after injection.  
In all rats,  blood pressure was measured 5 times with 
tail-cuﬀ plethysmography (Softron,  Tokyo,  Japan).
　 Visualization of glycocalyx by cationic col-
loidal iron staining. We visualized the glycoca-
lyx of retinal and choroidal capillary vessels by cat-
ionic colloidal iron staining as reported previously 
[18,  19].  Brieﬂy,  under ether inhalation anesthesia,  
the chest cavity was opened and blood was drawn from 
the right ventricle.  The rats were then perfused via 
the left ventricle with Ringerʼs lactate solution mixed 
with heparin.  Next,  the rats were ﬁxed with 2ｵ 
paraformaldehyde and 0.5ｵ glutaraldehyde in 0.1 M 
sodium cacodylate buﬀer (pH 7.4) and then perfused 
with cationic colloidal iron [18,  19].  The eyes were 
enucleated and postﬁxed with 1ｵ osmium tetroxide 
(Merck,  Darmstadt,  Germany) at 4℃ overnight.  The 
eyes were then embedded in Epon 812 (Oken Shoji,  
Tokyo,  Japan) and polymerized.  Finally,  we cut 
ultra-thin sections and observed the specimens under a 
transmission electron microscope (H-7100S; Hitachi,  
Tokyo,  Japan).
　 Quantiﬁcation of the thickness of the retinal 
and choroidal endothelial glycocalyx.
According to the method of Lindner JR et al.,  we used 
the transmission electron microgram (×30,000) and 
measured the distance from the luminal side of the 
VEC membrane to the luminal tip of the cationic col-
loidal iron deposit as the thickness of endothelial 
GCX [20].  The number of measuring points was at 
least 5 per vessel (WKY: n＝39 retinal and 16 chor-
oidal vessels; STZ-WKY: n＝29 retinal and 18 
choroidal vessels; and SHR: n＝33 retinal and 7 
choroidal vessels).  
　 Statistical analysis. The results are expressed 
as the mean±standard error of the mean (SEM).  
Data were analyzed by one-way ANOVA with Scheﬀeʼs 
test.  A p value of less than 0.05 was considered sta-
tistically signiﬁcant.  
Results
　 Table 1 shows the body weight,  blood glucose and 
blood pressure of WKY,  STZ-WKY and SHR at 16 
weeks after birth.  The blood glucose level of STZ-
WKY (437±47mg/dL) was signiﬁcantly higher than 
that of WKY (154±10mg/dL,  p＜0.01) and SHR 
(145±12mg/dL,  p＜0.01).  The systolic and dia-
stolic blood pressures of SHR (194±1mmHg,  153±
3mmHg,  respectively) were signiﬁcantly higher than 
those of WKY (116±3mmHg,  83±2mmHg,  respec-
tively,  both p＜0.01) and STZ-WKY (114±2mmHg,  
82±1mmHg,  respectively,  both p＜0.01).
　 We successfully visualized both the retinal and 
choroidal capillary glycocalyx by staining with cationic 
colloidal iron (Fig.  1 and 2).  In the control group 
278 Acta Med.  Okayama　Vol.  64,  No.  5Kumase et al.
(WKY),  the glycocalyx was situated evenly at the 
luminal side of all retinal and choroidal capillary ves-
sels.  Their thicknesses measured 60.2±1.5nm in the 
retina and 84.3±3.1nm in the choroid.  In STZ-WKY,  
the thickness of the retinal capillary glycocalyx was 
decreased signiﬁcantly (28.1±0.3nm,  p＜0.01,  Fig.  
1).  The thickness of the choroidal capillary glycocalyx 
in STZ-WKY did not change signiﬁcantly when com-
pared with that of WKY (77.8±1.4nm,  Fig.  2).  In 
the SHR group,  the thicknesses of both the retinal and 
choroidal capillary glycocalyx decreased signiﬁcantly 
(retinal capillary glycocalyx: 10.9±0.4nm,  p＜0.01,  
Fig.  1; choroidal capillary glycocalyx: 13.2±1.0nm,  
p＜0.01,  Fig.  2).
　 Fig.  3 shows representative electron microscopic 
images of leukocyte and platelet adhesion to the chor-
oidal VECs in STZ-WKY.  The glycocalyx decreased 
markedly in the adhesion area and its proximity.
Discussion
　 To our knowledge,  the present study is the ﬁrst to 
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Table 1　 Table 1 shows the physiological parameters of WKT, STZ-WKY and SHR at 16 weeks after birth.
Mean±SEM.  One-way ANOVA with Scheﬀeʼs test.  ＊: p＜0.01.
WKY STZ-WKY SHR
Body weight [g] 359±3 342±12 367±4
Blood glucose [mg/dL]  154±10  437±47＊ 145±12
Systolic blood pressure [mmHg] 116±3 114±2 194±1＊


































Fig. 1　 The thickness of the retinal glycocalyx was decreased in both diabetic and hypertensive rats.
Left,  Electron micrographs of the retinal microvessels of WKY,  STZ-WKY and SHR.  The glycocalyx was visualized by cationic colloidal 
iron particles (arrows).  Bar＝200nm; Right,  Thickness of the retinal glycocalyx of WKY,  STZ-WKY and SHR.  ＊: p＜0.01.
demonstrate that chronic hypertension degrades both 
retinal and choroidal GCX in rats.  We also showed 
the degradation of retinal GCX,  but not choroidal 
GCX,  in early diabetic rats.  In hyperglycemia,  it has 
been reported that both AGE and hyperglycemia itself 
cause systemic inﬂammation by producing proinﬂam-
matory cytokines such as tumor necrosis factor-a 
(TNF-a) [9,  21].  Henry et al.  and Mulivor et al.  
proposed that TNF-α activates leukocytes and VEC,  
and these cells produce reactive oxygen species (ROS) 
and proteases that degrade the GCX directly.  In 
hypertension,  Suematsu et al.  reported that chronic 
hypertension induces oxidative stress responses and 
decreases the production of ROS scavengers,  result-
ing in the degradation of the GCX [6].  Although the 
mechanism by which hyperglycemic and hypertensive 
conditions degrade the GCX in the retina and choroid 
remains unclear,  our results showed the eﬀect of 
these conditions on the homeostasis of retinal and 
choroidal GCX.
　 In the pathogenesis of diabetic and hypertensive 
vasculopathy,  leukocyte and platelet-endothelial adhe-
sion occurs as an inﬂammatory response to hypergly-
cemia,  AGE and high blood pressure [3,  22,  23].  In 
this process,  adhesion molecules such as integrin,  
selectin,  intercellular adhesion molecule-1 (ICAM-1) 
and vascular cell adhesion molecule-1 (VCAM-1) play 
a key role in binding leukocytes and platelets to the 
VEC [17].  Recently,  the GCX has been considered 
an antiadhesive factor in the process due to its rela-
tively large dimensions,  which exceed the length of 
these adhesion molecules [9].  For example,  in the 
heart,  the thickness of the GCX has been reported as 
50-500nm,  whereas ICAM-1 and P-selectin extend 
only 18.7nm and 38nm above the surface of the 
endothelium [9,  24].  In the control group (WKY) of 
the present study,  we showed that the GCX thick-
nesses of retinal and choroidal capillaries were 60.2
±1.5nm and 84.3±3.1nm,  respectively.  It has been 
reported that the number of leukocytes that adheres to 




































Fig. 2　 The thickness of the choroidal glycocalyx was decreased in hypertensive rats but not diabetic rats.
Left,  Electron micrographs of the choroidal microvessels of WKY,  STZ-WKY and SHR.  The glycocalyx was visualized by cationic colloidal 
iron particles (arrows).  Bar＝200nm; Right,  Thickness of the choroidal glycocalyx of WKY,  STZ-WKY and SHR.  ＊: p＜0.01.
the VECs reaches a maximum level in the very early 
phase of diabetic retinopathy—i. e.,  7 days after the 
STZ injection [17].  To detect the change in the GCX 
in this period,  we examined the diabetic rat choroidal 
capillaries on the 7th day after STZ injection and 
observed a degradation of the GCX at the site of leu-
kocyte and platelet-endothelial adhesion and its prox-
imity.  These ﬁndings coincide with the theory that the 
GCX functions as a barrier against proinﬂammatory 
stimuli in diabetes and hypertension.
　 In early diabetic rats (STZ-WKY),  the thickness 
of the retinal GCX decreased by 53ｵ compared to 
that of the control group (WKY).  However,  
Fitzgerald et al.  reported that the thickness of the 
retinal GCX did not change in spontaneous diabetic 
rats [25,  26].  As an explanation for the discrepancy,  
we consider that the diﬀerences in the method of GCX 
staining may have played a role.  After perfusion ﬁxa-
tion,  Fitzgerald et al.  stained the retinal GCX by 
immersing the tissue in cationized ferritin (CF),  
which binds to the GCX [25].  Then they quantiﬁed 
the amount of GCX by counting the number of CF 
particles.  On the other hand,  we stained the GCX by 
perfusion of cationic colloidal iron,  immediately after 
perfusion ﬁxation.  Because the GCX is attached to 
intravascular lumen,  perfusion staining is more eﬀec-
tive than immersion ﬁxation to stain the GCX.  
Furthermore,  the diameter of the colloidal iron par-
ticles (0.5-1.0nm) is much smaller than that of CF 
particles (12.0nm).  This enables us to improve the 
demonstration of GCX [18,  27].  Therefore,  we 
consider that their method may have lower sensitivity 
than our method and may underestimate the change in 
the length of GCX.  In humans,  it is well known that 
the incidence of diabetic choroidopathy is lower than 
that of retinopathy [28].  The result that the thick-
ness of choroidal GCX was not decreased (i. e.,  that 
the GCX was preserved) is compatible with this clini-
cal feature of diabetic ocular vasculopathy.  Although 
it is unclear why choroidal GCX is less vulnerable 
than retinal GCX,  our result suggests that the lower 
vulnerability of choroidal GCX may explain the 
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Fig. 3　 Degradation of the choroidal glycocalyx at the site of leukocyte and platelet adhesion.  Electron micrographs of leukocyte (A) 
and platelet (B) adhesion to choroidal vascular endothelial cells in STZ-WKY.  A leukocyte (A) and a platelet (B) adhered to the choroidal 
vascular endothelial cells.  In A,  the glycocalyx is degraded at the site of leukocyte adhesion and its proximity (arrows).  In B,  the glycoca-
lyx is totally degraded (arrows).  Bar＝500nm.
decreased occurrence of choroidal retinopathy.
　 Hypertension is the main secondary risk factor 
associated with diabetic retinopathy [29,  30].  Pinto 
et al.  reported that experimentally induced diabetes 
increases macrophage migration,  ICAM-1 expression,  
VEGF and NF-κB p65 levels in the SHR retina [30].  
In the present study,  not only diabetic rats (STZ-
WKY) but also hypertensive rats (SHR) showed deg-
radation of retinal and choroidal GCX.  Although we 
did not examine the model of diabetes associated with 
hypertension,  our results imply that hypertension can 
augment the degradation of GCX in diabetes and result 
in more severe diabetic retinopathy than diabetes 
alone.  
　 In conclusion,  we showed that 1) the length of both 
the retinal and choroidal GCX in WKY is longer than 
that of adhesion molecules; 2) the retinal GCX was 
degraded in both diabetic and hypertensive rats and the 
choroidal GCX was degraded in hypertensive rats; 3) 
the degradation of GCX coincided with leukocyte and 
platelet adhesion to VECs.  These ﬁndings suggest that 
the GCX functions as a protective factor in the patho-
genesis of retino- and choroidopathy in diabetes and 
hypertension.
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